FOXO3 and breast carcinoma: Reasoning that these findings might be extended to the identification of agents (such as small molecules) that can activate FOXO3a for development as a new tumor suppressive therapeutic modality in breast cancer, we studied the mechanisms by which FOXO3a suppressed the proliferation and tumorigenicity of MCF-7.